This trial will assess whether use of intraurethral 2% lidocaine jelly meaningfully impacts
sensation during filling (i.e., a change of more than 25% of first sensation, first desire to
void, strong desire to void, or maximum cystometric capacity) and determine whether the use
of intraurethral 2% lidocaine jelly meaningfully impacts pain/discomfort, filling metrics,
and voiding metrics.